Barras et al. also suggested different subtypes of BRAF-mutant CRCs based on gene expression, finding differences in immune regulating genes as well as patient survival, regardless of MSI, suggesting that the BRAF-mutated tumours are not uniform [42]. Here, BRAF is linked to neoplasm.